EXOZ

EXOZYMES INC.

3 filings tracked

healthcarebiotechnologyMICRO (<$300M)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 14

Filed S-3 shelf registration for up to $50 million to fund operations and expansion.

capital raise

90%

bearishMay 14

Net loss increased 27.7% year-over-year to $2.37 million.

earnings miss

70%

bearishMay 14

Operating costs rose 22.4% YoY driven by a 95% increase in R&D spending.

margin compression

60%

bearishMay 14

Severe liquidity shortage makes a dilutive equity offering necessary for survival.

dilution risk

80%

bullishMay 14

Filed S-3 shelf registration for up to $50 million to fund operations and expansion.

capital raise

90%

bearishMay 14

Net loss increased 27.7% year-over-year to $2.37 million.

earnings miss

70%

bearishMay 14

Operating costs rose 22.4% YoY driven by a 95% increase in R&D spending.

margin compression

60%

bearishMay 14

Severe liquidity shortage makes a dilutive equity offering necessary for survival.

dilution risk

80%

bearishMar 30

Net loss increased by 56% year-over-year to $9.16M with zero revenue.

margin compression

90%

neutralMar 30

Heavy reliance on government grants ($17.7M total) to fund pre-revenue operations.

capital raise

50%

neutralMar 30

Rebranding from Invizyne to eXoZymes to clarify cell-free technology positioning.

management change

30%

bearishMar 30

Significant concentration of ownership with MDB Capital holding 47.63% of common stock.

dilution risk

80%

Filing History

10-QMay 14, 2026

The Q1 2026 filing presents a classic high-risk, high-reward biotech profile: a company with validated, government-backed technology but a critically depleted treasury. The core tension lies in the race between the company's operational burn and its ability to execute the $50 million capital raise. While the increase in R&D spend suggests a push toward a commercial milestone, the collapse in working capital to $507,586 leaves virtually no margin for error. Ultimately, the filing reveals that eXoZymes is no longer in a phase of steady development but is instead in a fight for survival. The success of the upcoming public offering is the only viable catalyst that can transform the current liquidity crisis into a growth phase. Until such funding is secured, the company remains highly vulnerable to dilution and the inherent risks of pre-revenue synthetic biology development.

10-KMar 30, 2026

The 10-K filing reveals a company at a crossroads between a high-conviction technological breakthrough and a looming liquidity crisis. While the exozyme platform offers a compelling scientific alternative to synthetic biology, the financial data indicates a race against time to achieve commercial viability before cash reserves are exhausted. The transition to a 'nutraceutical-first' strategy is a pragmatic attempt to shorten the time to revenue, but the lack of an established distribution network and the reliance on external CMOs leave the company exposed to operational risks. Ultimately, the investment thesis hinges on whether the 2026 commercialization milestones for NCT can be met with the remaining capital. If eXoZymes can successfully secure a strategic partnership or a high-value licensing deal, it may validate its platform and unlock significant value. However, without a near-term infusion of capital or a rapid pivot to revenue, the company risks becoming a cautionary tale of a scientifically sound platform that failed to navigate the 'valley of death' of early-stage biotech commercialization.